Not available
Quote | Pacific Biosciences of California Inc. (NASDAQ:PACB)
Last: | $1.38 |
---|---|
Change Percent: | -0.74% |
Open: | $1.37 |
Close: | $1.38 |
High: | $1.42 |
Low: | $1.3 |
Volume: | 9,895,285 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Pacific Biosciences of California Inc. (NASDAQ:PACB)
2024-04-22 08:50:58 ET PacBio ( NASDAQ: PACB ) is facing yet another downgrade after the gene sequencing company lowered its full-year outlook, while missing Q1 results .... Read the full article on Seeking Alpha For further details see: PacBio moved to Neutral a...
2024-04-18 08:15:54 ET More on Pacific Biosciences of California Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript Why Is Pacific Biosciences' Price Action...
Message Board Posts | Pacific Biosciences of California Inc. (NASDAQ:PACB)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $PACB News Article - Biotech stock Pacific Biosciences could return 50% in 12 months: T | whytestocks | investorshangout | 03/31/2023 6:05:51 PM |
whytestocks: $PACB News Article - PacBio Launches Single-Cell Transcriptome Solution Ushering in a N | whytestocks | investorshangout | 10/20/2022 3:05:53 PM |
whytestocks: $PACB News Article - PacBio to Participate in the Morgan Stanley 20th Annual Global Hea | whytestocks | investorshangout | 09/07/2022 8:36:03 PM |
As I said earlier $4 coming! | OptimusPrime555 | investorshub | 08/22/2022 3:32:30 PM |
Back to $4 | OptimusPrime555 | investorshub | 08/15/2022 6:31:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Pacific Biosciences of California Inc. Company Name:
PACB Stock Symbol:
NASDAQ Market:
2024-04-18 06:00:04 ET Matthew Sykes from Goldman Sachs issued a price target of $2.50 for PACB on 2024-04-18 04:31:00. The adjusted price target was set to $2.50. At the time of the announcement, PACB was trading at $1.4. The overall price target consensus is at $5.50 w...
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results. The compan...
2024-04-17 09:15:03 ET Canaccord Genuity analyst issues BUY recommendation for PACB on April 17, 2024 07:10AM ET. The previous analyst recommendation was Buy. PACB was trading at $1.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...